MiNK Therapeutics (INKT) Current Assets (2020 - 2026)
MiNK Therapeutics (INKT) posted Current Assets of $10.0 million for Q1 2026, down 27.63% sequentially from $13.8 million in Q4 2025, and up 179.97% YoY from $3.6 million in Q1 2025.
MiNK Therapeutics (INKT) Current Assets (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Current Assets for 7 years, with the latest figure at $10.0 million in Q1 2026.
- Quarterly Current Assets rose 179.97% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 179.97% YoY) and the FY2025 annual result came in at $13.8 million, up 177.63% from the prior year.
- Current Assets declined to $10.0 million in Q1 2026 per INKT's latest filing, from $13.8 million in the prior quarter.
- Over five years, Current Assets peaked at $35.5 million in Q1 2022 and troughed at $2.0 million in Q2 2025.
- A 5-year average of $12.8 million and a median of $10.0 million in 2026 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets soared 610.7% in 2022, then slumped 82.37% in 2023.
- Over 5 years, Current Assets stood at $20.4 million in 2022, then plunged by 82.37% to $3.6 million in 2023, then soared by 38.62% to $5.0 million in 2024, then soared by 177.63% to $13.8 million in 2025, then declined by 27.63% to $10.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $10.0 million, $13.8 million, and $14.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 1.76 Bn |
| 10 | MiNK Therapeutics | 59.48 Mn | 59.48 Mn | - | 9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.30 Mn |
| Mar 31, 2026 | 10.02 Mn |
| Dec 31, 2025 | 13.85 Mn |
| Sep 30, 2025 | 14.53 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 3.58 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Sep 30, 2024 | 6.58 Mn |
| Jun 30, 2024 | 9.47 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 3.60 Mn |
| Sep 30, 2023 | 6.47 Mn |
| Jun 30, 2023 | 11.05 Mn |
| Mar 31, 2023 | 15.52 Mn |
| Dec 31, 2022 | 20.40 Mn |
| Sep 30, 2022 | 24.46 Mn |
| Jun 30, 2022 | 30.33 Mn |
| Mar 31, 2022 | 35.48 Mn |
| Dec 31, 2021 | 39.63 Mn |
| Sep 30, 2021 | 3.44 Mn |